Home/Filings/4/0001062993-23-015056
4//SEC Filing

Upton Richard A 4

Accession 0001062993-23-015056

CIK 0001842939other

Filed

Jul 17, 8:00 PM ET

Accepted

Jul 18, 8:36 PM ET

Size

12.8 KB

Accession

0001062993-23-015056

Insider Transaction Report

Form 4
Period: 2023-07-14
Transactions
  • Other

    Common Stock Warrants

    2023-07-14+895895 total(indirect: By LLC)
    Exercise: $6.71Exp: 2024-09-30Common Stock (895 underlying)
  • Other

    Common Stock Warrants

    2023-07-14+6969 total(indirect: Harbor Light Direct Investment, LP)
    Exercise: $6.71Exp: 2032-09-30Common Stock (69 underlying)
  • Award

    Stock Option (right to buy)

    2023-07-14+76,87876,878 total
    Exercise: $2.11Exp: 2031-09-23Common Stock (76,878 underlying)
Holdings
  • Common Stock

    (indirect: By LLC)
    1,230,484
  • Common Stock

    (indirect: Harbor Light Direct Investment, LP)
    108,535
Footnotes (5)
  • [F1]Mr. Upton is General Partner at Harbor Light Capital Partners, which is affiliated with the entities listed above. By virtue of this relationship, Mr. Upton may be deemed to share beneficial ownership of the securities held of record by the entities listed above. Mr. Upton disclaims any such beneficial ownership except to the extent of his pecuniary interest.
  • [F2]Options to purchase 76,878 shares of common stock of Legacy Carmell (as defined below) granted on September 23, 2021, which vest as follows: 25% vested on September 23, 2022 and the remaining 75% becomes vested in 36 equal monthly installments thereafter, subject to continued service through each vesting date.
  • [F3]On July 14, 2023, Alpha Healthcare Acquisition Corp. III ("ALPA") consummated a business combination (the "Business Combination") by and among ALPA, Candy Merger Sub, Inc., a Delaware Corporation ("Merger Sub") and Carmell Regen Med Corporation, a Delaware corporation ("Legacy Carmell"), ALPA changed its name to "Carmell Therapeutics Corporation" and Merger Sub merged with and into Legacy Carmell. As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation.
  • [F4]These warrants are currently exercisable.
  • [F5]As part of the Business Combination, existing warrants to purchase common stock of Legacy Carmell were exchanged for 0.06154 warrants to purchase shares of common stock of Carmell Therapeutics Corporation.

Issuer

ALPHA HEALTHCARE ACQUISITION CORP III

CIK 0001842939

Entity typeother

Related Parties

1
  • filerCIK 0001375726

Filing Metadata

Form type
4
Filed
Jul 17, 8:00 PM ET
Accepted
Jul 18, 8:36 PM ET
Size
12.8 KB